HC Wainwright Analysts Lift Earnings Estimates for CVKD

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) – Equities research analysts at HC Wainwright raised their Q2 2026 EPS estimates for shares of Cadrenal Therapeutics in a note issued to investors on Tuesday, July 21st. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings of ($0.95) per share for the quarter, up from their previous estimate of ($1.33). HC Wainwright currently has a “Buy” rating and a $13.00 target price on the stock. The consensus estimate for Cadrenal Therapeutics’ current full-year earnings is ($5.52) per share. HC Wainwright also issued estimates for Cadrenal Therapeutics’ Q3 2026 earnings at ($0.65) EPS, Q4 2026 earnings at ($0.75) EPS, FY2026 earnings at ($3.19) EPS and FY2027 earnings at ($3.09) EPS.

Several other analysts have also weighed in on CVKD. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Cadrenal Therapeutics in a research note on Friday, July 17th. Wall Street Zen upgraded Cadrenal Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, May 9th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $13.00.

Cadrenal Therapeutics Price Performance

Shares of CVKD opened at $2.10 on Thursday. The firm has a 50 day simple moving average of $3.70 and a two-hundred day simple moving average of $5.49. Cadrenal Therapeutics has a one year low of $2.05 and a one year high of $14.64. The company has a market cap of $6.51 million, a P/E ratio of -0.37 and a beta of 1.73.

Cadrenal Therapeutics (NASDAQ:CVKD) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($1.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.51) by $0.47.

Insider Activity

In other Cadrenal Therapeutics news, CEO Quang X. Pham sold 12,996 shares of the stock in a transaction that occurred on Friday, June 12th. The stock was sold at an average price of $3.94, for a total transaction of $51,204.24. Following the transaction, the chief executive officer directly owned 136,381 shares in the company, valued at approximately $537,341.14. This represents a 8.70% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In the last quarter, insiders sold 97,500 shares of company stock worth $388,290. 26.09% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Cadrenal Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Geode Capital Management LLC increased its position in Cadrenal Therapeutics by 14.3% in the 4th quarter. Geode Capital Management LLC now owns 14,528 shares of the company’s stock valued at $98,000 after buying an additional 1,818 shares in the last quarter. JPMorgan Chase & Co. bought a new position in shares of Cadrenal Therapeutics in the third quarter valued at approximately $103,000. DRW Securities LLC purchased a new stake in shares of Cadrenal Therapeutics during the 4th quarter valued at $171,000. Finally, Citadel Advisors LLC purchased a new stake in Cadrenal Therapeutics during the third quarter worth about $274,000. 7.92% of the stock is owned by institutional investors.

About Cadrenal Therapeutics

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.